Skip to main content

Table 3 Implant Utilization by Three Months (Primary Outcome) and Overall Contraceptive Use by Three Months (Secondary Outcome)

From: Primary and secondary three-month outcomes of a cluster-randomized trial of home-based postpartum contraceptive delivery in southwest Trifinio, Guatemala

  Total Population of Women who Initiated a Method by 3 Months (n = 208) Control Clusters [4] Women who Initiated a Method by 3 Months (n = 100, 48.1%) Intervention Clusters [4] Women who Initiated a Method by 3 Months (n = 108, 51.9%) P-Value RR [95% CI]
Using a Method by 3 Months     < 0.001 1.3
 Yes (% of total) 139 (66.8%) 56 (56.0%) 83 (76.8%)   [1.1, 1.5]
Method Being Used at 3 Months     < 0.001 5.6
 No Method 62 (29.8%) 44 (44.0%) 18 (16.7%)   [2.6,12.0]
 Abstinence 0 (0.0%) 0 (0.0%) 0 (0.0%)   
 Natural Family Planning 4 (1.9%) 1 (1.0%) 3 (2.8%)   
 Lactational Amenorrhea 0 (0.0%) 0 (0.0%) 0 (0.0%)   
 Condoms 1 (0.5%) 0 (0.0%) 1 (0.9%)   
 Pills 4 (1.9%) 0 (0.0%) 4 (3.7%)   
 Injection 99 (47.6%) 53 (53.0%) 46 (42.6%)   
 Implant 30 (14.4%) 2 (2.0%) 28 (25.9%)   
 Intrauterine Device 0 (0.0%) 0 (0.0%) 0 (0.0%)   
 Female Sterilization 1 (0.5%) 0 (0.0%) 1 (0.9%)   
 Male Sterilization 0 (0.0%) 0 (0.0%) 0 (0.0%)   
 Missing 7 (3.4%) 0 (0.0%) 7 (6.5%)   
Using a Short-Acting Methoda at 3 Months     0.72 0.98
 Yes (% of users) 104 (74.8%) 53 (94.6%) 51 (61.4%)   [0.8,1.1]
Using the Implant at 3 Months     < 0.001 1.3
 Yes (% of users) 30 (21.6%) 2 (3.6%) 28 (33.7%)   [1.2,1.4]
  1. Note: p-values the result of a generalized linear model mixed effects regression adjusted for cluster
  2. aShort Acting Method Includes: condoms, pills, injection